Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease
Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease
LONDON, Nov. 9, 2017 Download the full report: https://www.reportbuyer.com/product/5190777
Summary
Kidneys are highly specialized organs that maintain a stable internal environment of the body - referred to as homeostasis - by selectively excreting, retaining and secreting various substances according to specific needs. The kidneys serve a pivotal role in a number of basic physiological functions, including blood pressure control, salt and water homeostasis, blood cell production, acid-base balance, and calcium homeostasis.
Renal diseases are typically classified as either chronic or acute. CKD is asymptomatic at the early stages and often undiagnosed (Dousdampanis et al., 2012). CKD often exists alongside other conditions such as cardiovascular disease (CVD), diabetes and certain autoimmune diseases such as lupus. The risk of developing CKD increases with age.
Symptoms of renal diseases differ slightly between indications. Renal diseases are typically asymptomatic until relatively advanced renal failure is present. Pain is not a common symptom due to the lack of pain receptors in the kidney, except in some renal diseases that involve the ureter or the renal capsule, such as nephrolithiasis (kidney stones). In the early stages of renal disease, patients may only experience abnormalities in urine output or a presence of red blood cells and/or protein in the urine. In later stages, systemic symptoms may manifest, as well as signs of lost renal function, such as edema, fluid overload, electrolyte abnormalities and anemia.
Majority of marketed products for renal diseases are small molecules, which account for more than 95% of all products. There are only a small number of other molecule types - such as monoclonal antibodies (mAb) and proteins - available in the market.
The pipeline is highly diverse in terms of molecule type. Unlike the marketed products, the pipeline contains a wide range of other molecule types, including proteins, mAbs, synthetic peptides, cell therapies and vaccines. While small molecules account for majority of the marketed products, they only account for about 60% of the pipeline. This is partly due to the relatively large proportion of biologics.
Drug development for renal diseases has significantly lagged behind other therapy areas, and very few novel therapies have been approved in the last decade. The marketed pharmacotherapeutic treatments for renal diseases typically focus on controlling the risk factors and complications of renal failure. Treatments include anti-hypertensive agents, hormones, antibiotics, and systemic immunosuppressants.
The report "Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease" assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes.
Specifically, this report outlines -
- Analysis of renal diseases pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating renal diseases to overcome the level of unmet need.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: renal failure, glomerulonephritides, and renal scarring. Promising targets have been reviewed in greater detail.
- Visualize the composition of the renal diseases market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Scope
- With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
- There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?
Reasons to buy
- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the renal diseases market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the renal diseases pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating renal diseases to overcome the level of unmet need.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: renal failure, glomerulonephritides, and renal scarring. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the renal diseases deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals
Download the full report: https://www.reportbuyer.com/product/5190777
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article